American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular disease (CVD) Prevention
In-Person Event
Sep 15 - 17, 2017
Fort Lauderdale, Florida, USAOVERVIEW
American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular disease (CVD) Prevention is organized by American Society for Preventive Cardiology (ASPC) and would be held during Sep 15-17, 2017 at The Westin Fort Lauderdale Beach Resort, Fort Lauderdale, Florida, United States of America.
The target audience for this medical event for All healthcare professionals involved in the diagnosis, treatment, prevention and intervention of atherosclerotic cardiovascular disease, including physicians, pharmacists, nurse practitioners, nurses, physician assistants, dietitians, fellows and trainees. This CME Conference has been approved with a maximum of 12.75 AMA PRA Category 1 Credits.
Conference Objectives:
• Assess the implications of clinical trial outcomes for the future of preventive cardiology.
• Apply guidelines into clinical practice.
• Critically evaluate emerging evidence on heart failure management.
• Discuss the rationale for diagnostic screening of patient with atrial fibrillation.
• Describe effective interventions to maximize blood pressure control in patients with hypertension.
• Assess cardiac troponin testing and utility for prevention and risk stratification.
• Review recent advances within HDL science, including limitations of HDL as a biomarker, HDL dysfunction, and genetic associations of HDL lipoproteins with cardiovascular disease.
• Discuss how different diabetes medications can affect cardiac outcomes.
• Review strategies for improved diagnosis and treatment of heart disease in women.
• Outline evidence-based benefits and potential risks of hormone replacement therapy in men and women.
• Discuss strategies to initiate weight loss in patients who are overweight or obese.
• Review appropriate therapeutic interventions in complex clinical scenarios.
• Compare and contrast the utility of risk markers associated with LDL.
• Describe pharmacologic and non-pharmacologic therapies used for the treatment of dyslipidemia and the management of hypertriglyceridemia.
• Evaluate the use of lipoprotein (a) for CVD detection and treatment.
• Review the use of imaging modalities for primary prevention of CVD.
• Describe historical and recent trends in tobacco use behaviors and interventions to reduce use.
• Assess the role of advanced lipid testing in preventive cardiology.
The target audience for this medical event for All healthcare professionals involved in the diagnosis, treatment, prevention and intervention of atherosclerotic cardiovascular disease, including physicians, pharmacists, nurse practitioners, nurses, physician assistants, dietitians, fellows and trainees. This CME Conference has been approved with a maximum of 12.75 AMA PRA Category 1 Credits.
Conference Objectives:
• Assess the implications of clinical trial outcomes for the future of preventive cardiology.
• Apply guidelines into clinical practice.
• Critically evaluate emerging evidence on heart failure management.
• Discuss the rationale for diagnostic screening of patient with atrial fibrillation.
• Describe effective interventions to maximize blood pressure control in patients with hypertension.
• Assess cardiac troponin testing and utility for prevention and risk stratification.
• Review recent advances within HDL science, including limitations of HDL as a biomarker, HDL dysfunction, and genetic associations of HDL lipoproteins with cardiovascular disease.
• Discuss how different diabetes medications can affect cardiac outcomes.
• Review strategies for improved diagnosis and treatment of heart disease in women.
• Outline evidence-based benefits and potential risks of hormone replacement therapy in men and women.
• Discuss strategies to initiate weight loss in patients who are overweight or obese.
• Review appropriate therapeutic interventions in complex clinical scenarios.
• Compare and contrast the utility of risk markers associated with LDL.
• Describe pharmacologic and non-pharmacologic therapies used for the treatment of dyslipidemia and the management of hypertriglyceridemia.
• Evaluate the use of lipoprotein (a) for CVD detection and treatment.
• Review the use of imaging modalities for primary prevention of CVD.
• Describe historical and recent trends in tobacco use behaviors and interventions to reduce use.
• Assess the role of advanced lipid testing in preventive cardiology.
KEY DATES
15 Sep, 2017
Event Start Date
17 Sep, 2017
Event End Date
SPECIALITIES
CardiologySUGGESTED HOTELS
CONFERENCE VENUE
The Westin Fort Lauderdale Beach ResortRELATED CONFERENCES & LIVE WEBINARS
Quick Links